Top Health Tech Companies in Bengaluru (113)
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
Optum's Top Stability & Growth Strengths
Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.
Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.
Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.
Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.
Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.
ZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all. Founded in 1983, ZS has more than 15,000+ employees in over 40 offices worldwide.
ZS's Top Stability & Growth Strengths
Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.
Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.
Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.
At eClinical Solutions, our goal is to leverage technology to accelerate clinical research and bring life-changing therapies to patients faster. Our industry-leading elluminate® clinical data platform is used by top life sciences companies worldwide to regain control of their data and provide meaningful analytical insights.
eClinical Solutions's Top Stability & Growth Strengths
Strong Revenue Growth: Reported year-over-year software growth in 2024, alongside multi-year increases and net new client additions, indicates sustained commercial momentum. Customer penetration among large pharma is described as expanding across 2024–2025.
Investor Backing & Capital Strength: A majority investment by GI Partners, with Summit Partners remaining a minority investor, is described as supporting further scale, product investment, and global reach. This signals access to resources for continued expansion.
Strong Market Position & Advantage: Independent recognition as the highest-designated Leader in 2024 for life sciences clinical data and analytics platforms, coupled with adoption by numerous top biopharma companies, signals competitive strength in its core segment. Named client expansions further reinforce visibility and impact.
agilon health is transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients. Through our platform and partnership model, agilon health is leading the nation in creating the system we need – one built on the value of care, not the volume of fees. We honor the independence of local physicians and...
agilon health's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue increased substantially in 2024 to $6.06 billion, with quarterly results showing robust year-over-year gains. Membership on the platform also expanded meaningfully by year-end 2024, supporting the top line.
Strong Market Position & Advantage: The company operates one of the larger physician-enablement platforms focused on full-risk Medicare seniors, with a national footprint across 30+ communities and hundreds of thousands of covered lives. Its specialization in partnering with independent groups under global risk distinguishes it from broader, lighter-risk enablement peers.
Strategic Partnerships: Long-term arrangements with independent physician groups continued to expand with new marquee partners and entries into additional states. The partnership model provides aligned incentives and supports physician demand for enablement in value-based care.
Forus Health is a comprehensive full stack digital ophthalmology platform. With over 3.5M + transactions, FORUS HEALTH platform integrates devices, ophthalmologists, optometrists, AI engines etc to provide end to end ophthalmology screening services from anywhere, anytime. Forus Health 3nethra series of retinal cameras (classic, classic HD, classic 6.4 MB, classic GO) is a comprehensive range of adult retinal imaging cameras....
EPAM (NYSE:EPAM) is a global leader in AI transformation engineering and integrated consulting, serving Forbes Global 2000 companies and ambitious startups. With over thirty years of expertise in custom software, product and platform engineering, EPAM empowers organizations to become AI-Native enterprises, driving measurable value from innovation and digital investments. Recognized by industry benchmarks and leading analysts as a leader in...
EPAM Systems's Top Stability & Growth Strengths
Strong Market Position & Advantage: Analyst and client recognitions position EPAM as a leader in digital engineering and AI-enabled transformation, including multiple IDC MarketScape leadership placements and a Gartner recognition for custom software development. Independent coverage likewise describes the firm as a leading provider in these segments, reinforcing a durable competitive footing.
Resilient & Sustainable Growth: Revenue continues to expand year over year in recent quarters and on a trailing-twelve-month basis, and management still guides to growth for the current year despite a tougher backdrop. The pace has moderated compared with the prior year, but the trajectory remains positive.
Innovation-Driven Growth: The company is leaning into AI-native services and is identified as a leader in AI transformation engineering alongside strengths in data modernization and software engineering. This innovation-led mix is presented as a key engine for future expansion.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
Navitas Life Sciences delivers platform-driven full-service Clinical, Regulatory, and Safety solutions and services. Navitas operates across North America, Europe, Asia Pacific, and Latin America. Navitas brings together the capabilities of a full-service CRO, a technology-led life sciences services provider, and expertise in analytics and data sciences to address critical challenges and drive outcomes for life sciences. Navitas has over 30...
Powerful, integrated real-world data and AI-driven solutions to transform how insights are generated and accelerate therapeutic innovations to patients.
We are an analytics-driven, technology-enabled revenue cycle management company that alleviates financial and administrative burdens on healthcare providers by providing billing, coding, automation and analytics services. Our approach is simple: attention to detail and concern for accuracy. Learn more at agshealth.com
Rely HealthTech is a trusted healthcare technology company offering advanced Hospital Information Systems (HIS) and EMR software designed to simplify hospital operations. From patient registration to billing and reporting, Rely HealthTech provides end-to-end digital solutions for clinics, hospitals, and diagnostic centers. With real-time analytics, cloud-based access, and a user-friendly interface.
4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our...
JustTapOn is an emerging, autonomous platform dedicated to generating content across a multitude of categories and industries. With a focus on delivering high-quality information, the platform caters to diverse interests, including technology, weddings, marketing, business, education, entertainment, finance, healthcare, news, and travel. Operating from Bangalore, India, JustTapOn has rapidly positioned itself as a valuable resource for readers seeking insightful articles...
SigTuple combines the power of microfluidics, robotics, artificial intelligence (AI) and cloud computing to create smart diagnostic solutions which make quality healthcare delivery affordable and accessible. Since 2015, our efforts have been focused towards developing smart, automated solutions for basic, high volume diagnostic screening tests which improve the efficiency of doctors, enable tele-diagnostics and introduce a new paradigm of connected...
Remidio is an innovative ISO 13485 certified medical device company that seeks to create Healthcare Access by combining the simplicity of product design with cutting edge technology and sustainable business model innovations. Remidio uses principles of Design Thinking and involves key stakeholders during the product development process – clinicians, patients, and health workers, with a view to designing product solutions...
Driven by the vision of its Chairman, Dr. Prathap C. Reddy, the Apollo Hospitals Group pioneered corporate healthcare in India Over the last 25 years Apollo Hospitals has become the largest integrated private hospital group in Asia with expertise in managing hospitals, clinics, health insurance, healthcare IT, Telemedicine, Education, Pharmacy retail & Medical business process outsourcing. It owns & manages over...
Cureskin is an all-encompassing service that provides you with simple, tailored solutions with holistic lifestyle guidance to help keep your skin and hair looking healthy. At Cureskin, our mission is to assist you to achieve your skin and hair goals with our scientifically-backed dermatological solutions from the comfort of your home. All we need is a picture and using our...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Illumina's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Illumina maintains dominant leadership in short-read NGS with a broad installed base, end-to-end workflows, and wide adoption across research and clinical markets. This entrenched position supports recurring consumables pull-through and reinforces competitive advantage.
Profitability: Feedback suggests profitability and margins improved with a stronger year-end quarter, rising EPS, and robust free cash generation supporting restructuring and reinvestment. Operating performance strengthened year over year, indicating better cost discipline and a healthier earnings profile.
Innovation-Driven Growth: Feedback suggests product and technology innovation—including NovaSeq X adoption and advances in AI/informatics—is driving utilization and clinical momentum. Partnerships and acquisitions broaden multiomics capabilities and underpin a roadmap focused on further cost and throughput gains.

.jpg)


















-03.jpg)
.jpg)











